Hamill v. Collins

Rule Statements

The Tucker Act waives sovereign immunity for certain claims against the United States, including claims for money damages based on contract, tort, or statutory violations.

To prevail on a claim under the Tucker Act, a plaintiff must demonstrate that the government breached a contractual obligation, violated a statute or regulation that confers a right to money damages, or committed a tort for which the government is liable.

Remedies

Back payBenefits

Judges

• O'Malley

Q: What is Hamill v. Collins about?

Hamill v. Collins is a case decided by Federal Circuit on February 4, 2026.

Q: What court decided Hamill v. Collins?

Hamill v. Collins was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Hamill v. Collins decided?

Hamill v. Collins was decided on February 4, 2026.

Q: What is the citation for Hamill v. Collins?

The citation for Hamill v. Collins is . Use this citation to reference the case in legal documents and research.

Q: What is the full case name and citation for this decision?

The full case name is Hamill v. Collins, and it was decided by the United States Court of Appeals for the Federal Circuit (CAFC). Specific citation details would typically be found in legal databases.

Q: Who were the parties involved in the Hamill v. Collins case?

The parties involved were the patent holder, Hamill, and the party challenging the patent's validity, Collins. The dispute centered on the patentability of a method for treating a patient.

Q: What was the core dispute in Hamill v. Collins?

The central issue was whether a patent claiming a method for treating a patient with a specific genetic mutation using a particular drug was valid. The patent holder sought to protect this method, while the challenger argued it was not patentable subject matter.

Q: Which court decided Hamill v. Collins?

The United States Court of Appeals for the Federal Circuit (CAFC) decided the Hamill v. Collins case. This court has exclusive jurisdiction over appeals in patent cases.

Q: What was the outcome of the Hamill v. Collins case at the Federal Circuit?

The Federal Circuit affirmed the district court's grant of summary judgment, ruling that the patent claims at issue were invalid. The appellate court agreed that the claims did not meet the requirements for patentability.

Q: Is Hamill v. Collins published?

Hamill v. Collins is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Hamill v. Collins?

The court ruled in favor of the defendant in Hamill v. Collins. Key holdings: The court held that patent claims directed to a method of treating a patient with a specific genetic mutation using a known drug are invalid under 35 U.S.C. § 101 because they claim an abstract idea.; The court reasoned that the claims were directed to a natural phenomenon (the genetic mutation) and a mental step (identifying the mutation), which are not patent-eligible subject matter.; The court found that the claims did not add an 'inventive concept' sufficient to transform the abstract idea into a patent-eligible application, as the method involved merely administering a known drug to a patient identified as having the mutation.; The court distinguished this case from others where medical treatment claims were found patent-eligible, emphasizing that the claims here lacked a specific diagnostic step or a novel therapeutic technique beyond the natural phenomenon itself.; The court affirmed the district court's grant of summary judgment of invalidity, concluding that the claims were ineligible for patent protection..

Q: Why is Hamill v. Collins important?

Hamill v. Collins has an impact score of 75/100, indicating significant legal impact. This decision reinforces the Federal Circuit's strict interpretation of patent eligibility for diagnostic and treatment methods, particularly those involving natural phenomena. It signals that claims must offer more than just the identification of a natural correlation and the application of a known remedy to be patentable, potentially impacting innovation in personalized medicine.

Q: What precedent does Hamill v. Collins set?

Hamill v. Collins established the following key holdings: (1) The court held that patent claims directed to a method of treating a patient with a specific genetic mutation using a known drug are invalid under 35 U.S.C. § 101 because they claim an abstract idea. (2) The court reasoned that the claims were directed to a natural phenomenon (the genetic mutation) and a mental step (identifying the mutation), which are not patent-eligible subject matter. (3) The court found that the claims did not add an 'inventive concept' sufficient to transform the abstract idea into a patent-eligible application, as the method involved merely administering a known drug to a patient identified as having the mutation. (4) The court distinguished this case from others where medical treatment claims were found patent-eligible, emphasizing that the claims here lacked a specific diagnostic step or a novel therapeutic technique beyond the natural phenomenon itself. (5) The court affirmed the district court's grant of summary judgment of invalidity, concluding that the claims were ineligible for patent protection.

Q: What are the key holdings in Hamill v. Collins?

1. The court held that patent claims directed to a method of treating a patient with a specific genetic mutation using a known drug are invalid under 35 U.S.C. § 101 because they claim an abstract idea. 2. The court reasoned that the claims were directed to a natural phenomenon (the genetic mutation) and a mental step (identifying the mutation), which are not patent-eligible subject matter. 3. The court found that the claims did not add an 'inventive concept' sufficient to transform the abstract idea into a patent-eligible application, as the method involved merely administering a known drug to a patient identified as having the mutation. 4. The court distinguished this case from others where medical treatment claims were found patent-eligible, emphasizing that the claims here lacked a specific diagnostic step or a novel therapeutic technique beyond the natural phenomenon itself. 5. The court affirmed the district court's grant of summary judgment of invalidity, concluding that the claims were ineligible for patent protection.

Q: What cases are related to Hamill v. Collins?

Precedent cases cited or related to Hamill v. Collins: Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).

Q: What legal test did the Federal Circuit apply to determine patentability in Hamill v. Collins?

The Federal Circuit applied the Alice/Mayo two-step test to determine patentability. This test first asks whether the claims are directed to a patent-ineligible concept, such as an abstract idea or natural phenomenon, and if so, whether the claims contain an inventive concept sufficient to transform the abstract idea into a patent-eligible application.

Q: Why did the Federal Circuit find the patent claims in Hamill v. Collins invalid?

The court found the claims invalid because they were directed to an abstract idea, specifically a natural phenomenon (a genetic mutation) and a mental step (identifying the mutation). The court determined that the claims lacked an inventive concept sufficient to confer patent eligibility.

Q: What is an 'abstract idea' in the context of patent law, as discussed in Hamill v. Collins?

In patent law, an abstract idea refers to fundamental concepts or methods of organizing human activity, such as mathematical formulas, laws of nature, or methods of doing business. The Federal Circuit determined that the claims in Hamill v. Collins fell into this category by focusing on identifying a natural phenomenon and a diagnostic step.

Q: Did the Federal Circuit consider the drug used in the treatment method patentable?

The opinion focused on the patentability of the *method* of treatment, not the drug itself. The court's analysis centered on whether the claimed method, which involved identifying a genetic mutation and then treating it with a drug, was an abstract idea rather than a patent-eligible invention.

Q: What does it mean for a patent claim to be 'directed to a natural phenomenon'?

A patent claim is directed to a natural phenomenon if it essentially claims a law of nature, natural principle, or natural correlation. In Hamill v. Collins, the court viewed the identification of a specific genetic mutation as a natural phenomenon, and the subsequent treatment as inextricably linked to this natural discovery.

Q: What is the 'inventive concept' requirement in patent law, according to Hamill v. Collins?

The 'inventive concept' is the second step of the Alice/Mayo test. It requires that the patent claims add something significantly more than the abstract idea or natural phenomenon itself, such as a specific, practical application or an innovative technological improvement, to be patent-eligible.

Q: Did the claims in Hamill v. Collins add an inventive concept sufficient for patentability?

No, the Federal Circuit concluded that the claims did not add an inventive concept. The court found that merely identifying a genetic mutation and applying a known drug did not transform the abstract idea into a patent-eligible application, as it lacked a specific, practical application beyond the natural phenomenon.

Q: How does Hamill v. Collins relate to other patent eligibility cases like Alice Corp. v. CLS Bank International?

Hamill v. Collins applies the two-step framework established in Alice Corp. v. CLS Bank International. The Federal Circuit's reasoning in Hamill directly follows Alice by identifying the claims as directed to an abstract idea (natural phenomenon and mental step) and finding no inventive concept.

Q: What is the burden of proof for patent eligibility?

While the patent applicant bears the burden of proving patentability, the court's analysis in Hamill v. Collins focused on whether the claims, as written, met the statutory requirements for patent eligibility under Section 101 of the Patent Act. The district court granted summary judgment, indicating the issue was decided as a matter of law.

Q: How does Hamill v. Collins affect me?

This decision reinforces the Federal Circuit's strict interpretation of patent eligibility for diagnostic and treatment methods, particularly those involving natural phenomena. It signals that claims must offer more than just the identification of a natural correlation and the application of a known remedy to be patentable, potentially impacting innovation in personalized medicine. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: Who is most affected by the ruling in Hamill v. Collins?

This ruling primarily affects entities seeking to patent diagnostic methods, personalized medicine treatments, or methods that involve identifying natural phenomena and applying known therapies. It highlights the challenges in obtaining patent protection for such inventions under current patent eligibility standards.

Q: What are the implications for personalized medicine and genetic diagnostics?

The decision suggests that methods solely focused on identifying a genetic marker and applying a corresponding treatment may be difficult to patent. This could impact innovation and investment in personalized medicine, as companies may face challenges in securing exclusive rights for such discoveries.

Q: How might companies adapt their patent strategies after Hamill v. Collins?

Companies may need to focus on claiming specific technological improvements, novel diagnostic tools, or unique applications of treatments that go beyond simply identifying a natural phenomenon. Emphasizing the inventive steps and practical applications that transform the abstract idea could be crucial.

Q: Does this ruling prevent anyone from using the drug or treating the genetic mutation?

No, the ruling only invalidates the specific patent claims related to the method of treatment. It does not prevent the drug from being manufactured or sold, nor does it prohibit others from developing or using methods to treat the genetic mutation, provided they do not infringe on other valid patents.

Q: What is the potential impact on research and development in the pharmaceutical industry?

The ruling could encourage a shift in R&D focus towards patenting novel drug compounds or specific technological advancements in drug delivery or diagnostics, rather than broad treatment methods tied to genetic predispositions. It may also lead to more collaborative research if patent exclusivity is harder to obtain.

Q: How does this case fit into the broader history of patent eligibility for diagnostic and medical methods?

Hamill v. Collins continues a trend of increased scrutiny on patent eligibility for diagnostic and medical methods, following landmark Supreme Court decisions like Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Alice Corp. v. CLS Bank International, which have narrowed the scope of patentable subject matter.

Q: What legal precedent existed before Hamill v. Collins regarding patenting medical treatments?

Before Hamill, cases like Mayo and Alice had already established that laws of nature, natural phenomena, and abstract ideas are not patentable subject matter. These precedents set the stage for analyzing whether specific medical methods, particularly those involving diagnostics and natural correlations, contained an inventive concept.

Q: How has the interpretation of Section 101 of the Patent Act evolved leading up to this case?

Section 101 of the Patent Act defines patentable subject matter. Over time, judicial interpretations, particularly from the Supreme Court and the Federal Circuit, have refined the understanding of exceptions like abstract ideas and natural phenomena, leading to stricter application in cases like Hamill v. Collins.

Q: What was the docket number in Hamill v. Collins?

The docket number for Hamill v. Collins is 24-1543. This identifier is used to track the case through the court system.

Q: Can Hamill v. Collins be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: How did the case reach the Federal Circuit?

The case likely reached the Federal Circuit on appeal from a district court's decision. The district court had granted summary judgment in favor of Collins, finding the patent claims invalid. Hamill then appealed this decision to the Federal Circuit, which has exclusive jurisdiction over such patent appeals.

Q: What is 'summary judgment' and why was it granted in this case?

Summary judgment is a procedural device where a court resolves a case without a full trial if there are no genuine disputes of material fact and the moving party is entitled to judgment as a matter of law. The district court granted summary judgment because it concluded, as a matter of law, that the patent claims were invalid under Section 101.